In anemic ( baseline ) patients ( post hoc analysis ) , median survival was shorter in RCTH-treated ( 212 days ) versus RCHT + EPO-treated ( 343 days ) ( Hazard ratio = 1.62 [ 95 % CI : 0.99-2 .63 ] , p = 0.0525 ) .